Lilly boosts osteoporosis franchise, Zosano's IPO prospects
This article was originally published in Scrip
Executive Summary
Eli Lilly and Co's license for Zosano Pharma's transdermal osteoporosis drug candidate ZP-PTH could boost the big pharma company's own osteoporosis franchise, which took a big hit earlier this year when key patents expired for Evista (raloxifene) in March.